JF26-89 Veterinary Drugs

The Utah Division of Purchasing has issued a notice of intent to award a sole-source contract for veterinary drugs under solicitation number JF26-89, targeting the procurement of specialized compounded narcotics used for the safe capture of big game species including bison, moose, and elk. The contract, estimated at $27,224, requires the supply of potent opioid formulations—specifically Thiafentanil 10 mg/mL, Etorphine 10 mg/mL, Xylazine 300 mg/mL, Ketamine 200 mg/mL, and two proprietary combinations known as BAM and MK—exclusively from Wedgewood Pharmacy, as no other U.S.-based supplier can provide the precise drug combinations and concentrations required for wildlife management operations. This determination is grounded in the unique and irreplaceable nature of the products, which cannot be sourced elsewhere, fulfilling the condition under Utah’s Procurement Code that justifies non-competitive award due to the absence of alternative sources. The procurement falls under NAICS code 424210 and is classified as a purchase order to be performed within the state of Utah, with all freight costs prepaid by the vendor under F.O.B. Destination terms. The solicitation, posted on June 17, 2026, with a response deadline of June 24, 2026, is open for public contestation, allowing any qualified vendor to challenge the sole-source determination by submitting documentation that proves the existence of alternative suppliers capable of providing equivalent or superior products meeting the technical specifications. Contestants must also demonstrate their ability to deliver the exact proprietary formulations or their functional equivalents and, if applicable, provide a detailed cost comparison of transitional expenses associated with switching vendors. If no valid challenges are received by the deadline, the contract will be awarded directly to Wedgewood Pharmacy without a competitive bidding process, in compliance with state procurement exception rules. While the scope of work is clearly defined with specific drug formulations and quantities, critical contract elements such as delivery schedule, warranty, inspection procedures, payment terms, contractor representations, and performance period remain unspecified. Point of contact for the procurement is Jody Fetzer, with all communications directed through the designated state procurement system.